YKL-1-116

Overview

YKL-1-116 is a selective and covalent inhibitor of Cdk7 . YKL-1-116 does not target Cdk9 , Cdk12 , or Cdk13 . YKL-1-116 is more potent than THZ1 ( HY-80013 ) toward both Cdk7 WT and Cdk7 as , although Cdk7 as is relatively resistant to this compound as well.

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-116871
• CAS No.: 1957202-71-9
• Molecular Formula: C34H38N8O3
• Molecular Weight: 606.72
• Purity: 98.67%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source